Cited by 154Nerve injury and regenerationHereditary Neurological DisordersSirtuins and Resveratrol in Medicine

Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration

Open access
Yahata, Naoki, Yuasa, Shigeki, Araki, Toshiyuki·2009·The Journal of Neuroscience

Abstract

Studies of naturally occurring mutant mice,wld s, showing delayed Wallerian degeneration phenotype, suggest that axonal degeneration is an active process. We previously showed that increased nicotinamide adenine dinucleotide (NAD)-synthesizing activity by overexpression of nicotinamide mononucleotide adenylyltransferase (NMNAT) is the essential component of the Wld s protein, the expression of which is responsible for the delayed Wallerian degeneration phenotype in wld smice. Indeed, NMNAT overexpression in cultured neurons provides robust protection to neurites, as well. To examine the effect of NMNAT overexpression in vivo and to analyze the mechanism that causes axonal protection, we generated transgenic mice (Tg) overexpressing NMNAT1 (nuclear isoform), NMNAT3 (mitochondrial isoform), or the Wld s protein bearing a W258A mutation, which disrupts NAD-synthesizing activity of the Wld s protein. Wallerian degeneration delay in NMNAT3-Tg was similar to that in wld smice, whereas axonal protection in NMNAT1-Tg or Wld s(W258A)-Tg was not detectable. Detailed analysis of subcellular localization of the overexpressed proteins revealed that the axonal protection phenotype was correlated with localization of NMNAT enzymatic activity to mitochondrial matrix. Furthermore, we found that isolated mitochondria from mice showing axonal protection expressed unchanged levels of respiratory chain components, but were capable of increased ATP production. These results suggest that axonal protection by NMNAT expression in neurons is provided by modifying mitochondrial function. Alteration of mitochondrial function may constitute a novel tool for axonal protection, as well as a possible treatment of diseases involving axonopathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.4304-08.2009

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yahata, N., Yuasa, S., & Araki, T.
Affiliations
National Center of Neurology and Psychiatry (JP)
Venue
The Journal of Neuroscience
Published
2009-05-13
Volume
29
Issue
19
Pages
6276-6284
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2037726118
Cited by
154
References
30
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 10 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 5 · 2015: 10 · 2014: 12 · 2013: 16 · 2012: 16
FWCI
7.19
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Suzuken Memorial Foundation
  • Kowa Company
  • Kowa Life Science Foundation
  • Astellas Pharma
  • National Institute of Biomedical Innovation
  • Astellas Foundation for Research on Metabolic Disorders
  • Mishima Kaiun Memorial Foundation
  • Japan Society for the Promotion of Science (19650089)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
nicotinamide mononucleotide adenylyltransferase, NMNAT3, NMNAT1, Wallerian degeneration, axonal degeneration, axonal protection, mitochondrial matrix, NAD biosynthesis, mitochondrial function, ATP production, transgenic mice, axonopathy
MeSH terms
Adenosine Triphosphate, Animals, Axons, Electron Transport, Mice, Transgenic, Mitochondria, Nerve Tissue Proteins, Neurons, Nicotinamide-Nucleotide Adenylyltransferase, Sciatic Nerve, Wallerian Degeneration, Mutation, Missense, Sciatic Neuropathy, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review